TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3377946

Group type: COMPARATOR
Intervention: Extradural morphine 3 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.18 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.09 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All groups (morphine 3 mg, buprenorphine 0.18 mg, buprenorphine 0.09 mg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Morphine 3 mg and buprenorphine 0.18 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 57
Study: 31009834

Group type: COMPARATOR
Intervention: Single SUD
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Poly-SUD
Number of subjects: 54
Study: 28152251

Group type: EXPERIMENTAL
Intervention: Proton hypofractionated radiotherapy (RT)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Carbon ion hypofractionated radiotherapy (RT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal-appearing control tissue
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Different PSA thresholds
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PSA relapse criteria according to Vancouver rules
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 18-month measurements
Number of subjects: 92
Study: 27520283

Group type: EXPERIMENTAL
Intervention: Tailoring + video-coaching
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tailoring only
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 151

Group type: COMPARATOR
Intervention: Tailoring + video-coaching vs Waitlist control
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 151
Study: 24337919

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Invasive therapy (primary PCI)
Number of subjects: 850
Study: 23058017

Group type: EXPERIMENTAL
Intervention: 1000 AU of LAIS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3000 AU of LAIS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 20008695

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 20)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 36
Study: 17551699

Group type: EXPERIMENTAL
Intervention: 50 mg chlorazepate dipotassium (CD) in the evening and 25 mg CD in the morning, placebo 30 min prior to anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: 7.5 mg midazolam on demand, placebo in the evening
Number of subjects: 50
Study: 15543228

Group type: EXPERIMENTAL
Intervention: Physical Activity multilevel intervention (ICAPS)
Number of subjects: 954
Study: 11452128

Group type: EXPERIMENTAL
Intervention: Activation of mu-opioid receptor system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous opioids
Number of subjects: 0
Study: 9452284

Group type: EXPERIMENTAL
Intervention: Artesunate suppositories (15 mg/kg/day for three days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oral artesunate (6 mg/kg/day for three days)
Number of subjects: 52
Study: 7629484

Group type: EXPERIMENTAL
Intervention: Methimazole 60 mg day‐1 combined with thyroxine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Methimazole alone (low-dose)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intention to treat analysis for high-dose group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intention to treat analysis for low-dose group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thyroid volume in relapsed patients
Number of subjects: 56
Study: 2774647

Group type: EXPERIMENTAL
Intervention: Suspension-type ointment (0.0056% betamethasone-17-benzoate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Solution-type ointment (0.0056% betamethasone-17-benzoate)
Number of subjects: 31
Study: 779588

Group type: EXPERIMENTAL
Intervention: Debrisoquine (3 X 10 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methyldopa (3 X 250 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31288016

Group type: EXPERIMENTAL
Intervention: TAVR-AA (transcatheter aortic valve replacement via alternative access)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: TAVR-TF (transcatheter aortic valve replacement via transfemoral)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: TAVR-TF in hybrid OR
Number of subjects: 81

Group type: COMPARATOR
Intervention: Use of RADPAD (disposable radiation shielding)
Number of subjects: 81
Study: 29603656

Group type: EXPERIMENTAL
Intervention: Early guidance
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Late guidance
Number of subjects: 33

Group type: COMPARATOR
Intervention: No guidance/control
Number of subjects: 33
Study: 28838980

Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg q.d
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Fevipiprant 75 mg b.i.d
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg q.d
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study: 25797640

Group type: EXPERIMENTAL
Intervention: Acupuncture on KI1 (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acupuncture on DU26 (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acupuncture on both KI1 and DU26 (group C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham acupuncture (group D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No acupuncture (group E)
Number of subjects: 50
Study: 24028643

Group type: EXPERIMENTAL
Intervention: Temazepam 7.5 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Acetazolamide 125 mg
Number of subjects: 34
Study: 21426664

Group type: EXPERIMENTAL
Intervention: Weekly usage of paclitaxel (45 mg/m², 1 time/week, total 270 mg/m² in 6 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Triple weekly usage of paclitaxel (15 mg/m², 3 times/week, total 270 mg/m² in 6 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 38
Study: 20078535

Group type: EXPERIMENTAL
Intervention: Minimal incision aortic surgery (MIAS)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard open repair
Number of subjects: 37
Study: 17876174

Group type: EXPERIMENTAL
Intervention: Enhanced decision aid
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual Care decision aid
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Enhanced decision aid (previous digital rectal examination)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual Care decision aid (previous digital rectal examination)
Number of subjects: 198
Study: 14725515

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with 0.0002% fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.1% levobupivacaine with 0.0002% fentanyl
Number of subjects: 60
Study: 11208880

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Surgery and chemotherapy
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Surgery and tamoxifen
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Surgery, tamoxifen, and chemotherapy
Number of subjects: 1259

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 1259
Study: 9692100

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal oxygen for 1 week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nocturnal room air for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal oxygen
Number of subjects: 20
Study: 1515565

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg per os
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6540930

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional palliative regimen without corticoid therapy
Number of subjects: 36
Study: 30809728

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic technique
Number of subjects: 156

Group type: COMPARATOR
Intervention: 2D laparoscopic technique
Number of subjects: 156
Study: 30152275

Group type: EXPERIMENTAL
Intervention: NAVIGATE
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 404
Study: 26790405

Group type: EXPERIMENTAL
Intervention: Acute inspiratory muscle loading at 60% of maximal inspiratory pressure (PImax)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Acute inspiratory muscle loading at 2% of maximal inspiratory pressure (PImax, placebo load)
Number of subjects: 14
Study: 23612677

Group type: EXPERIMENTAL
Intervention: TPN + preOp
Number of subjects: 75

Group type: COMPARATOR
Intervention: NIL
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TPN
Number of subjects: 75
Study: 21935438

Group type: EXPERIMENTAL
Intervention: Tailor-made notched music training (TMNMT) for patients with tinnitus frequencies ≤8 kHz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tailor-made notched music training (TMNMT) for patients with tinnitus frequencies >8 kHz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tailor-made notched music training (TMNMT)
Number of subjects: 20
Study: 19597011

Group type: EXPERIMENTAL
Intervention: Maternal and infant antiretroviral therapy, elective cesarean section, avoidance of breast-feeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mother-to-child transmission coverage rates for HIV-positive women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmet need for antiretroviral therapy
Number of subjects: 0
Study: 18172379

Group type: EXPERIMENTAL
Intervention: Needle social marketing programme
Number of subjects: 823

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 823
Study: 14694459

Group type: EXPERIMENTAL
Intervention: Acupuncture reflexotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11172505

Group type: EXPERIMENTAL
Intervention: Triple-injection method (group III) - ulnar nerve not located
Number of subjects: 84

Group type: COMPARATOR
Intervention: Four-injection method (group IV) - all nerves located
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (group III and group IV)
Number of subjects: 84
Study: 10985714

Group type: EXPERIMENTAL
Intervention: Surgery and/or pericardiocentesis for patients with rupture or tamponade (27 out of 28 patients)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Patients with rupture or tamponade
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Overall shock cohort
Number of subjects: 1048
Study: 7656626

Group type: EXPERIMENTAL
Intervention: Single-step cold-dry air challenge (CACh)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Histamine challenge
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Correlation between CACh and histamine challenge
Number of subjects: 128
Study: 2562472

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 7
Study: 875803

Group type: EXPERIMENTAL
Intervention: New absorbent bed pad (Kylie)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drawsheets
Number of subjects: 0
Study: 31309977

Group type: EXPERIMENTAL
Intervention: 16-week exercise intervention (aerobic and resistance exercise 3 times per week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 100
Study: 28089080

Group type: EXPERIMENTAL
Intervention: Salba‐chia (30 g/1000 kcal/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Oat bran-based control (36 g/1000 kcal/day)
Number of subjects: 77
Study: 25545441

Group type: EXPERIMENTAL
Intervention: One corticosteroid course
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Repeat corticosteroid course
Number of subjects: 1652
Study: 23190213

Group type: EXPERIMENTAL
Intervention: Indie rock scenes
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Electronic dance music scenes
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Lesbian parties
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Alt scenes
Number of subjects: 1781

Group type: COMPARATOR
Intervention: Hip-hop scenes
Number of subjects: 1781
Study: 21269346

Group type: EXPERIMENTAL
Intervention: Weekly Unna boot therapy
Number of subjects: 10
Study: 19298724

Group type: EXPERIMENTAL
Intervention: Mean Platelet Component (MPC) measurement in patients with CAD
Number of subjects: 324
Study: 16810752

Group type: EXPERIMENTAL
Intervention: Endoscopic resection using a ligation device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional endoscopic resection
Number of subjects: 15
Study: 14687806

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 34
Study: 10705939

Group type: EXPERIMENTAL
Intervention: Bilateral parietotemporal hypoperfusion in patients with severe AD, early onset symptoms, and men.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Bilateral parietotemporal hypoperfusion in patients with early onset symptoms.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Bilateral parietotemporal hypoperfusion in male patients.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Duration of symptoms, type of gamma‐camera or radiopharmaceutical agent used.
Number of subjects: 220
Study: 9493655

Group type: EXPERIMENTAL
Intervention: Zileuton (400 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7810174

Group type: EXPERIMENTAL
Intervention: Lupanine (40.26 mumol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 13-hydroxylupanine (37.83 mumol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lupanine and 13-hydroxylupanine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lupin seed
Number of subjects: 11
Study: 3392126

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (16 IU/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (32 IU/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate (control)
Number of subjects: 0
Study: 29635864

Group type: EXPERIMENTAL
Intervention: Promoting efficacy regarding EVD
Number of subjects: 447

Group type: COMPARATOR
Intervention: Emphasizing threat
Number of subjects: 447
Study: 28185995

Group type: EXPERIMENTAL
Intervention: 12-step mutual help group linkage intervention (individual meeting with a volunteer in jail and post-release support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (providing schedules for local 12-step meetings)
Number of subjects: 0
Study: 26271331

Group type: EXPERIMENTAL
Intervention: On-site coaching intervention focused on SCC; duration: 4-6 weeks; modified to peer-to-peer coaching and strengthened training.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified intervention implemented in three additional facilities; peer-to-peer coaching and enhanced leadership engagement.
Number of subjects: 0
Study: 22925046

Group type: EXPERIMENTAL
Intervention: Web-based alcohol assessment and personalized feedback (intervention)
Number of subjects: 1789

Group type: COMPARATOR
Intervention: Screening alone (control)
Number of subjects: 1789
Study: 20882293

Group type: EXPERIMENTAL
Intervention: Countermovement jumps at 50° knee angle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Countermovement jumps at 70° knee angle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Countermovement jumps at 90° knee angle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volitional effort at 25%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Volitional effort at 100%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sub-maximal jumps
Number of subjects: 10
Study: 19882857

Group type: EXPERIMENTAL
Intervention: Ultraviolet autoblood irradiation (UVABI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard complex therapy without UVABI
Number of subjects: 0
Study: 16546539

Group type: EXPERIMENTAL
Intervention: 4.0% chlorhexidine
Number of subjects: 15123

Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 15123

Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 15123
Study: 14510038

Group type: EXPERIMENTAL
Intervention: Telecommunications case management
Number of subjects: 213

Group type: COMPARATOR
Intervention: In-person case management
Number of subjects: 213

Group type: COMPARATOR
Intervention: Limited case management services from primary drug counselors
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Other drug use
Number of subjects: 213
Study: 11112029

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 57

Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 57
Study: 9339804

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 microg/ml), 5 drops three times a day for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gentamicin sulfate (5 mg/ml), 5 drops three times a day for 10 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Gentamicin sulfate (both groups)
Number of subjects: 40
Study: 8244604

Group type: EXPERIMENTAL
Intervention: Cosmed K2 system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Douglas bag method
Number of subjects: 20
Study: 2412037

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg, b.i.d. for 2 weeks, then doubled)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Propranolol (40 mg, b.i.d. for 2 weeks, then doubled)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Ketanserin and Propranolol
Number of subjects: 331
Study: 30160787

Group type: EXPERIMENTAL
Intervention: 2% tofacitinib ointment applied twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1% ruxolitinib ointment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topical clobetasol dipropionate 0.005% ointment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Generalized hair regrowth
Number of subjects: 16
Study: 27344195

Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling intervention for smoking cessation
Number of subjects: 1837
Study: 23900641

Group type: EXPERIMENTAL
Intervention: 300 mg of L‐3,4‐dihydroxyphenylalanine (L‐DOPA)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 23351674

Group type: EXPERIMENTAL
Intervention: KO Palu NightWatch activities
Number of subjects: 519000
Study: 21418609

Group type: EXPERIMENTAL
Intervention: Accelerometer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pedometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: IPAQ
Number of subjects: 30
Study: 18376656

Group type: EXPERIMENTAL
Intervention: Moderate-pressure irrigation system
Number of subjects: 0
Study: 16860613

Group type: EXPERIMENTAL
Intervention: AGA II IgA
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: AGA II IgG
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Gluten-free diet after 6 months
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Gluten-free diet after 1 year
Number of subjects: 92

Group type: COMPARATOR
Intervention: AGA II compared to conventional AGA
Number of subjects: 92

Group type: COMPARATOR
Intervention: AGA II compared to antitissue transglutaminase antibodies
Number of subjects: 92
Study: 12673141

Group type: EXPERIMENTAL
Intervention: Glucose supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (no glucose supplementation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Baseline (no exercise)
Number of subjects: 8
Study: 10870980

Group type: EXPERIMENTAL
Intervention: SK and F 107647 (1, 10, 100, 500, and 1000 μg/kg as single 15-minute iv infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SK and F 107647 (0.001, 0.01, 0.1 and 1 μg/kg as 2-hour iv infusions once daily for 10 days)
Number of subjects: 0
Study: 10164045

Group type: EXPERIMENTAL
Intervention: Cost-sharing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health insurance coverage
Number of subjects: 0
Study: 1900978

Group type: EXPERIMENTAL
Intervention: Flecainide 150 mg twice per day for 3 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 6797513

Group type: EXPERIMENTAL
Intervention: Emission computed tomography (emission CT)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Planar gamma‐camera imaging
Number of subjects: 242

Group type: COMPARATOR
Intervention: Transmission (x‐ray) CT
Number of subjects: 242
Study: 31851388

Group type: EXPERIMENTAL
Intervention: Socially isolated older adults
Number of subjects: 2015

Group type: COMPARATOR
Intervention: Not socially isolated older adults
Number of subjects: 2015
Study: 31200092

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28403972

Group type: EXPERIMENTAL
Intervention: 7mmHg with AirSeal® system
Number of subjects: 60

Group type: COMPARATOR
Intervention: 15mmHg standard insufflator
Number of subjects: 60
Study: 25450717

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 8 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 40 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 120 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg
Number of subjects: 51
Study: 23939326

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VRG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 60
Study: 20678825

Group type: EXPERIMENTAL
Intervention: In-person professional interpreter services
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (no interpreter services)
Number of subjects: 447
Study: 19476428

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Menactra
Number of subjects: 2180